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Objectives: Clinicians treating patients with advanced NSCLC have a range of 
options for care. The objective of this study was to develop a cost-effectiveness 
(CE) model to compare induction-maintenance sequences approved for use in the 
U.S. for the treatment of advanced non-squamous NSCLC given the absence of 
direct head-to-head trials. MethOds: The modelled regimens that were licensed 
in the United States included pemetrexed+cisplatin followed by (→ ) pemetrexed; 
pemetrexed+cisplatin→ best supportive care (BSC); gemcitabine+cisplatin→ BSC; 
gemcitabine+cisplatin→ erlotinib; gemcitabine+cisplatin→ pemetrexed; and pac
litaxel+carboplatin+bevacizumab→ bevacizumab. Treatment effects of induction 
and maintenance on survival endpoints were obtained using data from a previ-
ous network meta-analysis. Decision analytic modelling was used to synthesise 
the treatment effect and baseline risk estimates for the induction and mainte-
nance treatment sequences. The CE model was structured using an area-under-
the-curve approach, costs and benefits were discounted at 3.5% per annum, 
and probabilistic and one-way sensitivity analyses were conducted to evaluate 
model parameters. Results: All active maintenance therapy-containing regi-
mens, with the exception of gemcitabine+cisplatin→ erlotinib, were more costly 
than induction-only regimens. Gemcitabine+cisplatin→ BSC was the baseline 
comparator and established the cost effective threshold range of $0 to $121,425. 
The respective incremental costs per life year (LY) were $121,425, $148,994, and 
$191,270 for gemcitabine+cisplatin→ erlotinib versus gemcitabine+cisplatin→ BSC, 
pemetrexed+cisplatin→ BSC versus gemcitabine+cisplatin→ erlotinib, and 
pemetrexed+cisplatin→ pemetrexed versus pemetrexed+cisplatin→ BSC. 
Other regimens were dominated (paclitaxel+carboplatin+bevacizumab→ beva-
cizumab) or extendedly dominated (gemcitabine+cisplatin→ pemetrexed). 
Sensitivity analyses demonstrated that efficacy data and the method of extrap-
olating survival had the greatest impact on the cost-effectiveness results. 
For non-dominated regimens, the cost-effectiveness acceptability frontier 
showed that gemcitabine+cisplatin→ BSC, pemetrexed+cisplatin→ BSC, and 
pemetrexed+cisplatin→ pemetrexed had the greatest probabilities of cost-effec-
tiveness over the following threshold ranges: $0-$124,000/LY; $124,000-$220,000/
LY; and above $220,000/LY, respectively. cOnclusiOns: Depending on the specific 
cost-effectiveness threshold used by a decision maker, the cost-effective treatment 
sequence will be gemcitabine+cisplatin→ BSC, gemcitabine+cisplatin→ erlotinib, 
pemetrexed+cisplatin→ BSC, or pemetrexed+cisplatin→ pemetrexed. Paclitaxel+c
arboplatin+bevacizumab→ bevacizumab and gemcitabine+cisplatin→ pemetrexed 
were dominated or extendedly dominated and thus not cost-effective when rank-
ing these comparators.
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Objectives: As antiretroviral therapy is scaled up in Africa, HIV-positive women 
are increasingly likely to die from cervical cancer, a leading cause of cancer death. 
Effective screens for cervical cancer exist including Papanicolaou smear (Pap), 
visual inspection of the cervix with acetic acid (VIA), and human papillomavirus 
testing (HPV). Our objective was to prospectively assess cost-effectiveness of cervi-
cal cancer screening methods for HIV-positive women. MethOds: The analysis 
was based on data from 500 HIV-positive women who underwent VIA, Pap, HPV, 
and gold-standard colposcopy-directed biopsy in Nairobi, Kenya. A Markov model 
projected life expectancy and costs for six cervical screening strategies: Pap; VIA; 
HPV; testing positive for both VIA+Pap, Pap+HPV, VIA+HPV. Cost-effectiveness was 
calculated for overall population and by CD4 count. Strategies were compared 
using an incremental cost-effectiveness ratio (ICER)—the additional cost per life 
year (LY) gained. Impact of parameter uncertainty was addressed using univariate 
and probabilistic multivariate sensitivity analysis. Results: VIA had lowest cost 
and highest life expectancy ($331, 17.2 LYs), followed by HPV ($569, 17.1 LYs), Pap 
($622, 17.1 LYs), HPV+Pap ($836, 17.0 LYs), VIA+HPV ($857, 17.0 LYs), and VIA+Pap 
($897, 17.0 LYs). CD4 level did not affect this rank order, though VIA at low CD4 
showed the lowest cost ($111, 15.3 LY), while VIA at high CD4 produced most health 
gains ($285, 19.9 LY) [ICER: $37/LY]. Costs were sensitive to prevalence of cancer, 
sensitivity, age, and cost of cancer. Life expectancy was sensitive to age at screen-
ing. Results were robust to probabilistic sensitivity analysis. cOnclusiOns: VIA 
is projected to be the most cost-effective screening strategy for cervical cancer 
among HIV-positive women. This is due to its high sensitivity, low screening cost, 
low risk treatment, and high cervical cancer cost. Screening women with high 
CD4 is particularly cost-effective. VIA should be implemented among HIV-positive 
women in low-income settings.
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Objectives: 10-20% of patients diagnosed with prostate cancer progress to meta-
static castration-resistant prostate cancer (mCRPC). Recently, four novel therapies 
have been introduced for the treatment of mCRPC; of these, abiraterone and sip-
uleucel-T have been studied in the asymptomatic, pre-docetaxel population. Both 
have shown clinical benefits compared to placebo. This study evaluated the cost-
effectiveness of abiraterone acetate and sipuleucel-T compared to prednisone in 
asymptomatic, pre-docetaxel mCRPC from a US societal perspective. MethOds: 
A Markov model was constructed to simulate stable disease, progressed disease, 
and death. Survival and event rates were derived from published clinical trial data. 
Costs were derived from the literature and government reimbursement schedules. 
Utilities were derived from the literature. Outcomes were measured as average 
cost-effectiveness ratios (ACER), incremental cost-effectiveness ratios (ICER), and 
net monetary benefits (NMB). One-way and probabilistic sensitivity analyses were 
ing imatinib. MethOds: A retrospective study spanning July 2004-December 2011 
analyzed data from 3 large integrated claims databases. Patients with a GIST-related 
ICD-9-CM code (151.0-154.0, 158.0, 159.0, 159.8, 159.9, 171.0, 171.4-171.9, 239.0) receiv-
ing imatinib were eligible if they (1) had a minimum eligibility of 6 months prior 
and 12 months following their first GIST diagnosis and (2) no previous diagnosis of 
cancer. Patients were divided into 2 cohorts: surgical (S) and non-surgical (NS). ST 
treatment patterns and corresponding GIST-related average monthly costs were evalu-
ated. Results: There were 57 (24 S, 33 NS), 98 (62 S, 36 NS), and 276 (156 S, 120 NS) 
patients in each of the 3 databases meeting all inclusion criteria, respectively. Average 
monthly cost of first-line therapy ranged from $26,465 to $78,081, with variation being 
driven by length of treatment. 42%-56% of NS and 41%-58% of S patients received 
second-line therapy, costing an average of $3,197-$5,334 per month. The majority of 
patients in each database received imatinib mono- or combination therapy as second-
line treatment (60%-74% NS; 74%-86% S). Third-line therapy was received by 13%-33% of 
NS and 19%-30% of S patients, with an average cost per month ranging from $2,354 to 
$30,993. Imatinib was also received third-line by the majority of the patients in 2 data-
bases (59%-67% NS, 60-75% S); sunitinib was most commonly utilized (43% NS, 58% S) in 
the third database. cOnclusiOns: Over half of all patients receiving imatinib undergo 
surgery. Among both S and NS patients, second-line therapy for GIST was dominated 
by imatinib, while third-line therapy was dominated by imatinib or sunitinib.
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Objectives: This study aimed to elucidate the hospitalization costs of adverse 
events (AEs) commonly associated with treatments for metastatic mela-
noma. MethOds: Based on current drug labels and published clinical studies for 
the treatments of metastatic melanoma, 23 serious adverse events were identified. 
Length of stay (days) and hospitalization costs (2013 US $) for these 23 events (identi-
fied by primary discharge diagnoses) were examined using a large national claims 
database, in which patients with metastatic melanoma were identified from July 
2004 to November 2012. All analyses are presented descriptively. Results: There 
were 2998 patients with metastatic melanoma: most were male (59.5%) and the 
mean age was 55.8 years old. Hospitalizations due to acute myocardial infarction 
and sepsis incurred the longest median length of stay (9 and 6 days, respectively), 
followed by acidosis (5.5 days), acute kidney failure, pneumonitis, neuropathy, 
thrombocytopenia, and oliguria/anuria (all had 5 days). The highest inpatient cost 
per event was for acute myocardial infarction (mean $45,971 and median $53,747), 
followed by sepsis ($34,351 and $22,838), coma ($30,943 and $23,149), acute kidney 
failure ($30,485 and $19,972), neuropathy ($28,977 and $12,034), and pneumonitis 
($27,669 and $21,011). Colitis/diarrhea, cutaneous squamous cell carcinoma, throm-
bocytopenia, hyponatremia, oliguria/anuria, hypertension, anemia, and elevated 
liver enzymes were associated with mean costs per hospitalization ranging from 
$26,234 to $18,676. In contrast, the lower inpatient cost per event was for cellulitis 
(mean $16,828 and median $12,045), fever ($15,078 and $13,650), rash ($14,432 and 
$12,086), and nausea ($13,715 and $10,892). cOnclusiOns: Hospital costs for the 
management of adverse events vary greatly. This study provides source data for 
economic evaluation of treatments for metastatic melanoma.
PCN84
heAlth iNsurer burdeN of PAtieNt reCAll folloWiNg breAst CANCer 
sCreeNiNg MAMMogrAPhy
Bonafede M.M.1, Miller J.D.1, Lenhart G.M.1, Nelson J.2, Fajardo LL3
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA, 
3University of Iowa College of Medicine, Iowa City, IA, USA
Objectives: A high percentage of patients recalled after screening mammography do 
not have cancer. The goal of this study is to describe the prevalence and cost to health 
plans of patient recall in the 6 months following screening mammography. MethOds: 
The Truven Health MarketScan Commercial and Medicare Supplemental Databases were 
used to identify women aged 40-75 years undergoing screening mammography (index 
event) in 2010-2012. Women were required to have 12 months pre- and 6 months 
post-index continuous enrollment. Women with mammography or a breast cancer 
diagnosis in the 12 month pre-index period were excluded. Recall was defined as 
receipt of a second breast-related imaging procedure, coinciding with an abnormal 
mammogram diagnosis code or a breast-related diagnosis in the 6 months following 
the index screen. Payer cost per recall (2012 US$) was the sum of breast-related imagin-
ing procedures and associated visit costs in the 6 months post-index, excluding patient 
payments. Breast cancer treatment costs were not included in recall costs. Results: 
Of the 1,553,044 women who met the study inclusion criteria, 246,233 (15.9%) had 
an abnormal mammogram or related diagnosis code and had a subsequent imaging 
procedure in the 6 months post-index. The average cost per patient recalled was $1,082 
in the 6 months following screening mammography. The majority of recalls included 
diagnostic mammography (71.8%) or ultrasound (51.9%), which accounted for 12% and 
9% of recall costs, respectively. Office visits and pathology services accounted for 42% 
of recall costs. Biopsy was performed in 19.3% of recalled patients and accounted for 
27% of recall costs. MRI, fine needle aspiration, and ductogram accounted for < 5% of 
recall costs. cOnclusiOns: Approximately one-in-six women undergoing screening 
mammography were recalled for further imaging within 6 months, with an average 
cost to health plans of $1,082 per patient. Improving breast cancer screening with a 
more accurate mammogram may significantly reduce payer costs.
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